Patents by Inventor John H. Krystal

John H. Krystal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180318288
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: July 10, 2018
    Publication date: November 8, 2018
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Patent number: 10052318
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 21, 2018
    Assignee: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Publication number: 20170360775
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 21, 2017
    Applicant: YALE UNIVERSITY
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Publication number: 20170181966
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: January 27, 2017
    Publication date: June 29, 2017
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20170173039
    Abstract: The present invention provides compositions and methods comprising talampanel and/or perampanel for treating or preventing an addictive disease or disorder, such as alcoholism, in a subject in need thereof. AMPA receptor (AMPA-Rs) antagonists (i.e., blockers), such as perampanel and talampanel, reduce drug and alcohol seeking behaviors in mammals since activation of glutamatergic AMPA receptors promotes addictive behaviors in mammals.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Inventors: Albert ARIAS, Ismene PETRAKIS, John H. KRYSTAL
  • Publication number: 20170151191
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: December 14, 2016
    Publication date: June 1, 2017
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, JR., John H. Krystal
  • Patent number: 9592207
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 14, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Patent number: 9539220
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: January 10, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human Services
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20150056308
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: June 17, 2014
    Publication date: February 26, 2015
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20140256821
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicants: Icahn School of Medicine at Mount Sinai, National Institute of Health, Yale University School of Medicine
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
  • Publication number: 20140249173
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Application
    Filed: May 15, 2014
    Publication date: September 4, 2014
    Inventors: Vladimir Coric, John H. Krystal, Gerald Sanacora
  • Patent number: 8785500
    Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: July 22, 2014
    Assignees: Icahn School of Medicine at Mount Sinai, Yale University, National Institute of Health
    Inventors: Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, Jr., John H. Krystal
  • Patent number: 8778979
    Abstract: Methods of treating mental disorders, including anxiety disorders such as obsessive-compulsive disorder, are provided. The methods comprise administering an effective amount of a glutamate modulator to an individual in need thereof. Also provided are methods of enhancing the activity of a serotonin reuptake inhibitor (SRI) comprising co-administering a glutamate modulator and a serotonin reuptake inhibitor. Pharmaceutical composition comprising a serotonin reuptake inhibitor and a glutamate modulator are also provided.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: July 15, 2014
    Assignee: Yale University
    Inventors: Vladimir Coric, John H. Krystal, Gerard Sanacora
  • Patent number: 5447948
    Abstract: Mazindol and other dopamine and/or noradrenergic reuptake inhibitors are effective to treat negative symptoms in schizophrenia.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: September 5, 1995
    Assignee: Yale University
    Inventors: John P. Seibyl, John H. Krystal, Dennis S. Charney